Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — H1 FY27 Earnings Presentation
15 slides from Morepen Laboratories's earnings presentation, Oct 27, 2026
Slide 1: Exchange filing intimation letter
Date: 27/10/2026 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288 Subject: Investor Presentation – Q2 & H1 FY27 Dear Sir/ Madam, Pl
Slide 2: Building Today. Transforming Tomorrow.
Building Today. Transforming Tomorrow. Q2 & H1 FY27 Investor Presentation Advancing Chemistry. Creating Possibilities. Transformation in Motion 1
Slide 3: Q2'FY27 - From Validation to Transformation
Q2'FY27 - From Validation to Transformation Revenue EBITDA EBITDA Margin PAT Rs. 755 Cr Rs. 132 Cr 17.45% Rs. 89 Cr +81% +273% +897 bps +117% YoY YoY YoY YoY yoy Second consecutive quarter of record revenue and earnings CDMO commercial supplies scale up materially 2
Slide 4: H1'FY27 - Morepen Enters a New Earnings Scale
H1'FY27 - Morepen Enters a New Earnings Scale Revenue EBITDA EBITDA Margin PAT Rs. 1330 Cr Rs. 220 Cr 16.50% Rs. 145 Cr +57% +243% +894 bps +177% YoY YoY YoY YoY Two consecutive quarters establish a materially stronger earnings profile. 3
Slide 5: A Stronger Earnings Profile. Better Capital Efficiency.
A Stronger Earnings Profile. Better Capital Efficiency. ROCE ROE Receivables Debt / Equity TTM Ratios 18.8% 13.6% 49 days 0.23x 9.4% FY26 7.6% FY26 66 days FY26 0.17x FY26 The earnings transformation is now visible in returns, working capital and financial capacity. 4
Slide 6: Q2'FY27 - CDMO Scale-Up
Q2'FY27 - CDMO Scale-Up Rs. 58 Cr Rs. 253 Cr 4.3x 52% Q1- CDMO Q2- CDMO Q-o-Q Q2- Share of Revenue Revenue API + CDMO Revenue CDMO crosses 52% of API + CDMO revenue 5
Slide 7: API - Moving Up the Value Curve
API - Moving Up the Value Curve Long-standing leadership in key APIs 25% Exporting to over 90 countries New Molecules Share of API Revenue H1 FY27 Deep, long-standing global customer relationships. vs 14% in H1 FY26 ~76% of API revenue from exports API remains the scientific & manufacturing foundati
Slide 8: Revenue Mix Becomes More Global
Revenue Mix Becomes More Global Q1 exports grew 111% YoY +122% H1 Export Revenue Q2 exports grew 131% YoY YoY Growth H1 export revenue: Rs. 654 Cr, up 122% YoY 50% Exports now represent ~50% of company’s sales revenue Export Share of Sales Revenue vs 35% H1 FY26 Growth increasingly led by global, hi
Slide 9: Four Transformations Driving Morepen 2.0
Four Transformations Driving Morepen 2.0 Revenue Mix Earnings Profile Lower-margin mix >> Higher- API-led >> API+CDMO+Devices quality earnings More global revenue mix Higher operating leverage Longer-duration programmes Greater reinvestment capacity Scale Capability Manufacturing base >> Established
Slide 10: Transformation Flywheel
Transformation Flywheel Higher-Quality, Longer- Higher Duration Revenues earnings Larger Reinvestment programmes Morepen 2.0 Stronger Scale + Innovation capability Investment Each transformation creates the next phase of growth 9
Slide 11: Proof: Commercial CDMO Execution
Proof: Commercial CDMO Execution Rs. 825 Cr Rs. 311 Cr 52%+ 614 KL Global CDMO H1 CDMO Q2 Share of Capacity Mandate Revenue API + CDMO Commissioned (Feb’26) Revenue ahead of schedule Q2 FY27 earnings strength enables the next phase of expansion. 10
Slide 12: Medical Devices – A Scalable Chronic-Care Franchise
Medical Devices – A Scalable Chronic-Care Franchise Q2 Revenue Leadership:: Glucose + BP Monitoring Leadership Rs. 208 Cr Installed Base: Base: ~20 Mn meters +65% Consumables:: ~500 Mn strips p.a. Consumables H1 Revenue All-India Distribution + Service Backward-Integrated Manufacturing Rs. 399 Cr Op
Slide 13: A Stronger Platform for the Next Phase
A Stronger Platform for the Next Phase ESG API + CDMO ZLD / solar / customer Higher-value mix / requirements chemistry foundation Regulatory Devices USFDA / ANDA / Scalable chronic- global credentials care franchise. A diversified, compliant and scalable platform for long-term growth. 12
Slide 14: The Canvas Is Expanding
The Canvas Is Expanding Today Building Creating A Stronger Earnings Base Scale & Capability A Larger Opportunity Commercial CDMO execution Capacity expansion Larger global programmes Higher-value API platform Innovation Hub Longer-duration Scalable Devices franchise New technologies partnerships Hig
Slide 15: Safe Harbour Statement
Safe Harbour Statement This presentation has been prepared by Morepen Laboratories Limited (“Morepen” or the “Company”) for informational purposes only and does not constitute an offer, invitation, recommendation, or solicitation to purchase or subscribe to any securities. Certain statements contain